Dianthus Therapeutics (DNTH) Cash from Operations Growth (3y) (2020 - 2025)

Dianthus Therapeutics (DNTH) Cash from Operations Growth (3y) (2020 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Dianthus Therapeutics 3.37 Bn 2.97 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 -56.95%
Jun 30, 2025 -12.34%
Mar 31, 2025 -11.86%
Dec 31, 2024 -20.49%
Sep 30, 2024 -14.77%
Jun 30, 2024 -3.77%
Mar 31, 2024 3.78%
Dec 31, 2023 4.79%
Sep 30, 2023 11.53%
Jun 30, 2023 37.31%
Mar 31, 2023 14.85%
Dec 31, 2022 17.26%
Sep 30, 2022 50.71%
Jun 30, 2022 -3.88%
Mar 31, 2022 -9.74%
Dec 31, 2021 -7.52%
Sep 30, 2021 -10.07%
Jun 30, 2021 -12.59%
Mar 31, 2021 -20.43%
Dec 31, 2020 -18.60%